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   A B S T R A C T    
  O b j e c t i v e       T  o determine the contribution of herpes 
simplex virus (HSV) to serious neurological disease.   
  Setting  and  patients      A 3-year prospective survey of 
children aged 2–23 months in Britain and Ireland.   
  R e s u l t s       19 children had HSV central nervous 
system (CNS) infection; 13 aged 2–11 months had 
focal neuroimaging abnormalities and 11 long-term 
neurological sequelae. Of six aged 12–35 months, 
one had abnormal neuroimaging and three long-
term neurological sequelae. 17 of the 19 had serious 
neurological disease. HSV CNS infection accounted for 
23% of serious neurological disease in children aged 
2–11 months and 4.5% in older children.   
  C o n c l u s i o n s       The incidence of HSV-induced serious 
neurological disease in the UK was estimated at 1 in 
64 000/year in younger children and 1 in 230 000 in 
older children. HSV CNS infection has clinical effects 
ranging from frank encephalitis to severe illness 
with fever and convulsions to milder disease lacking 
e n c e p h a l o p a t h y.       
  I N T R O D U C T I O N   
  H  erpes simplex encephalitis (HSE) is the most 
common cause of sporadic encephalitis and with-
out treatment 70% of patients die. Our knowledge 
o f  HS E  r e li e s  o n  tw o  clini cal  tri als  o f  an ti vir al  
drugs from the 1980s. Since then substantial 
changes in diagnostic methods, including PCR 
to test cerebrospinal ﬂ  uid (CSF) for herpes sim-
plex virus (HSV) DNA together with the use of 
aciclovir, have improved survival. However, the 
spectrum of clinical manifestations and long-
term outcome need to be better deﬁ  ned so as to 
improve management and thereby decrease the 
still considerable morbidity and mortality associ-
ated with this devastating condition. 
  A prospective survey of children aged 
2–23 months in Britain and Ireland with serious 
neurological disease showed for the ﬁ  rst  time 
that human herpesvirus-6 and -7 contributed sig-
niﬁ  cantly to this illness.  1   Data collected included 
information on other pathogens, including HSV, 
and thus its contribution to the burden of disease 
could be assessed. The present paper reports the 
results obtained.   
  M E T H O D S  
  P a t i e n t s  
  Case  ascertainment 
  Between October 1998 and September 2001 paedi-
atricians were requested by the British Paediatric 
Surveillance Unit to report the cases of all   children 
2–35 months old with serious neurological dis-
ease.  1   Neonates were excluded from the survey 
to avoid inclusion of inherited and mechanical 
neurological damage which often presents before 
2 months of age. Details of each child’s neurologi-
cal illness were collected using a short standard 
questionnaire. A further brief questionnaire was 
sent after at least a year to check long-term out-
come, that is, whether the child had recovered 
or suffered developmental delay, persisting neu-
rological deﬁ   cit or convulsions. An additional 
questionnaire was sent to the referring hospital’s 
microbiology laboratory to conﬁ  rm the microbi-
ological results at the time of the child’s illness. 
Each questionnaire was scrutinised by a physi-
cian (KNW) to determine whether the details 
ﬁ   tted the case deﬁ   nition (see below). Difﬁ  cult 
cases were referred to one or more paediatricians 
(AO, CMV, EMR) for a ﬁ  nal decision. The data-
base of all reported disease episodes, regardless of 
whether or not they met the case deﬁ  nition, was 
re-examined by KNW for individuals with HSV 
central nervous system (CNS) infection.     
  D e ﬁ nitions 
  F e v e r  
  Fever was deﬁ  ned as a temperature ≥37.5°C.   
  Serious  neurological  disease    
  1.  Severe illness with fever and convulsions 
  i .            with a total duration of >30 min 
  ii.       followed by encephalopathy for 2–23 h 
  iii.          followed by paralysis or other neuro-
logical signs not previously present for 
≥24 h. 
 2.            Encephalitis 
  i .              Encephalopathy for ≥24 h and two or 
more of the following: 
    a .             fever 
    b .         convulsions 
    c .         focal neurological ﬁ  ndings (≥24 h) 
    d .         pleocytosis (>5 leucocytes/μl CSF) 
    e .           characteristic abnormal CT or MRI 
results. 
 3.        Exclude 
  i .               viral (aseptic) meningitis without 
encephalopathy 
  i i .           the following conﬁ  rmed causes: hypoxic/
ischaemic, vascular, toxic, metabolic, neo-
plastic, traumatic and pyogenic infections 
  iii.          uncomplicated convulsions or a series of 
convulsions lasting <30 min 
  iv.        immunocompromised children. 
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     HSV  CNS  infection 
      HSV DNA detected in CSF or an HSV-speciﬁ  c intrathecal  1. 
antibody response, or 
      Evidence of primary HSV infection, that is, seroconversion  2. 
to IgG or IgM, within 2 weeks of onset of serious neurologi-
cal disease.         
  Ethics  approval 
  Ethics approval was given by the Public Health Laboratory 
Service Ethics Committee, London.     
  R E S U L T S  
    Cases of serious neurological disease 
  Of the 267 episodes of disease reported, 19 cases of HSV CNS 
infection (  table 1  ) and 163 cases of serious neurological dis-
ease were identiﬁ  ed; 52 of the latter were in children aged 
2–11 months and 111 in children aged 12–35 months.   
  The clinical features, neuroimaging results and long-term 
outcome of the 19 cases are given in   table 2  . Every case pre-
s e n te d  wi th  c o n vuls i o ns  ( p arti al  in  1 2 / 1 9 )  a c c o m p ani e d  b y  
fever in all but one instance. Focal neuroimaging abnormali-
ties were noted in all children aged <11 months (temporal 
lobes in nine, frontal lobes in three and parietal lobes in seven) 
but in only one of the older children. T  here were no deaths, 
but 11 of the 13 children aged 2–11 months and three of the six 
older children had long-term neurological sequelae. The most 
common sequela was developmental delay, but other persist-
ing deﬁ   cits included hemiparesis, quadriparesis and visual 
  problems. Eight children had epilepsy.   
  Two patients (nos. 12 and 15) with HSV CNS infection did 
not meet our case deﬁ  nition of serious neurological disease. 
The remaining 17 (11 encephalitis, six severe illness with 
fever and convulsions) accounted for 23% (12/52) of episodes 
of serious neurological disease in children <1 year old and 
4.5% (5/111) in the older children. Because all 17 cases were 
in British children, we could estimate the incidence of serious 
neurological disease due to HSV CNS infection in the UK as 1 
in 64 000/year in children aged 2–11 months and 1 in 230 000/
year in children aged 12–35 months. In 1998–2001 there were 
2.1 million children in the ﬁ  rst year of life and 4.1 million in 
the second and third years (National Statistics Ofﬁ  ce website: 
  http://www.statistics.gov.uk/popest  ).     
  DISCUSSION 
  T  his paper reports data on the incidence, spectrum of clinical 
presentation and long-term outcome of virologically conﬁ  rmed 
HSV CNS infection in young children throughout the British 
Isles. So that milder cases would be included, the deﬁ  nition of 
HSV CNS infection covered more than just serious neurologi-
cal disease, which in turn comprised not only encephalitis but 
also severe illness with fever and convulsions. 
  Thus only 58% of the children with HSV CNS infection 
in the survey had an illness that ﬁ  tted our strict deﬁ  nition 
of encephalitis as the remainder did not fulﬁ  l the criterion of 
encephalopathy for ≥24 h. Such atypical forms of HSV CNS 
infection have been previously reported  2     3   and together with 
our ﬁ  ndings show that HSV is responsible for more than clear-
cut encephalitis in young children. 
  Cases may have been missed in our survey because HSV 
DNA or pleocytosis may not be found in CSF soon after dis-
ease onset. Likewise, aciclovir treatment may result in the 
absence of CSF HSV DNA and delay antibody seroconversion. 
 Table  1        HSV CNS infection: results of laboratory investigations   
 Patient  no. 
 CSF 
 Intrathecal 
antibody synthesis 
 Seroconversion  to 
IgG or IgM  †  
 WBC  (lymphocytes)/
RBC per µl   Protein  (g/l)   Viral  DNA *  
17  ( N T ) / 1 3 1 0 0 . 8 H S V   ‡ NT NT
2 35 (35)/3500 0.55 HSV  ‡ NT NT
3 25 (25)/3 0.47 HSV-1 NT NT
4 23 (18)/<1 0.6 Negative NT Yes
5 93 (93)/295 0.5 HSV-1 NT NT
62  ( N T ) / 1 2 0 . 6 8H S V   ‡ NT Yes
7 560 (280)/900  § 1.03 HSV-1 NT NT
8 7 (NT)/50 0.34 HSV-1 NT NT
97 0  ( 7 0 ) / 4 0 0 . 3 2N e g a t i v e Y e s N T
10 21 (21)/115 1.01 HSV-1 NT NT
11 97 (NK)/50  ¶ 1.0 HSV-1 NT NT
12 120 (85)/2510 NT HSV-1 NT NT
13 NT NT NT NT Yes
14 <1 (<1)/50 0.23 HSV-1 NT NT
15 <1 (<1)/<1 NK HSV-1 NT NT
16 1 (1)/10 0.14 HSV-1 NT NT
17 NK (NK)/NK NK HSV  ‡ NT NT
18 NT NT NT NT Yes
19 10  (10)/37 *  *  1.06 HSV  ‡  NT NT
   *   T e s t e d   f o r   b y   P C R .   
  †    Within 2 weeks of onset of serious neurological disease.   
  ‡  Virus  not  typed.  
  §    First CSF nothing abnormal detected.   
  ¶  First  CSF  clotted.  
  *   * First  sample  WBC  <1/RBC  per  µl  127.  
    CNS, central nervous system; CSF, cerebrospinal ﬂ  uid; HSV, herpes simplex virus; NK, not known; NT, not tested; 
RBC, red blood cell; WBC, white blood cell.     
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Indeed, nowadays CSF is rarely tested for intrathecal HSV 
antibody  4   and this was certainly our experience. Finally, the 
declining use of HSV serum antibody tests together with a 
decrease in the use of lumbar puncture in paediatric practice 
may have affected detection.  5   However, it seems that in fact 
few cases were missed. Analysis of Hospital Episode Statistics 
(HES) for England over 1998–2001 gives 52 cases of HSE in 
children <3 years old (data not shown). This ﬁ  gure is necessar-
ily higher than ours since it includes neonates in whom HSE 
occurs in appreciable numbers (76 cases in 1986–1991, 83 cases 
in 2004–2006).  6   Thus, although the HES data lack conﬁ  rma-
tory virological evidence and a uniform case deﬁ  nition, they 
 Table  2        HSV CNS infection: clinical features, neuroimaging and long-term outcome   
 Patient  (n/sex/age)   Fever  (°C)   Encephalopathy   Convulsions  (duration)    Lesions on CT    Lesions on MRI    Outcome (time after discharge  *  ) 
1/F/3 months Yes (39.2) 2–23 h Whole body (>30 min) Haemorrhagic R and L 
hemispheres, oedema
ND Developmental delay (  cognitive 
and motor), spastic quadriplegia, 
blind, whole body convulsions 
(2 years)
2/F/4 months Yes  †   (NK) ≥24 h Partial, L hemiclonic 
(>30 min)
Haemorrhagic R and L 
temporal and parietal
ND Developmental delay (cognitive), 
behavioural problems (4 years)
3/M/5 months Yes (38.2) ≥24 h Partial (<15 min) Haemorrhagic R and L 
parietal, low density R 
and L temporal and R 
parieto-occipital
ND Developmental delay (  cognitive 
and motor), hypotonia, L homony-
mous hemianopia (10 months)
4/M/6 months Yes (38.2) ≥24 h Partial (>30 min) and 
L hemiplegia ≥24 h
Low density bifrontal ND Developmental delay (  cognitive 
and motor), L hemiplegia, whole 
body convulsions (3 years)
5/M/6 months Yes (38) ≥24 h Partial L-sided 
(>30 min) and L 
 hemiplegia  ≥24 h
Haemorrhagic, low den-
sity L frontal, temporal 
and parietal
R cerebral 
hemisphere
Developmental delay (  cognitive 
and motor), L hemiplegia and con-
vulsions (2 years)
6/F/6 months Yes (38.8) ≥24 h Partial motor 
(>30 min) and 
L   hemiplegia ≥24 h
R parietal, occipital ND Developmental delay (  cognitive 
and motor), L homonymous hemi-
anopia (1.5 years)
7/F/6 months Yes (38) 2–23 h Whole body (>30 min) Low density frontal, 
temporal, parietal
R and L frontal and 
temporal, R pari-
etal oedema and 
haemorrhage
Developmental delay (  cognitive 
and motor), quadriparesis, convul-
sions, atonic attacks (2.5 years)
8/M/8 months Yes (38.5) ≥24 h Partial, R-sided 
with oculogyric crisis 
(>30 min)
Low density temporal 
lobe
ND Recovered (1 year)
9/F/10 months Yes (NK) ≥24 h Whole body 
(15–30 min)
Low density R temporal 
and parietal
R temporal 
– no normal 
parenchyma
Developmental delay (  cognitive 
and motor), autism, convulsions 
(4 years)
10/F/10 months Yes (38.5) ≥24 h Whole body (<15 min) Low density R and 
L   temporal lobe, ser-
piginous enhancement 
R   sylvian ﬁ  ssure
ND Developmental delay (  cognitive) 
(1 year)
11/F/10 months Yes (39) ≥24 h Partial (>30 min) Low density L temporal 
lobe
R temporal hae-
morrhagic and L 
temporal, parietal 
and occipital
Developmental delay (  cognitive 
and motor), R hemiplegia, R hom-
onymous hemianopia, convulsions 
(2 years)
12/F/11 months Yes (39.5) <2 h Partial (15–30 min) 
and Todd’s paresis  ‡ 
Low density L 
temporal
ND Recovered (2 years)
13/F/11 months Yes (38.6) 2–23 h Partial, R-sided 
(>30 min) and 
Todd’s paresis
Haemorrhagic R 
parietal lobe
R and L haemor-
rhagic parietal and 
parasagittal
Needs speech therapy (2 years)
14/F/14 months Yes (37.8) ≥24 h Partial, clonic R arm 
(15–30 min)
Normal ND Recovered (NK)
15/F/17 months No NK  §  Whole body (>30 min) Normal ND Convulsions, absences but attends 
normal school (2.5 years)
16/F/17 months Yes (39.2) <2 h Whole body (>30 min) Normal ND Recovered (1 year)
17/F/18 months Yes (39.0) 2–23 h Whole body (<15 min) 
and ataxia ≥24 h
Normal Diffuse high signal 
in white matter 
around ventricles
Hemiparesis (2.5 years)
18/M/26 months Yes (37.5) ≥24 h Partial (>30 min), 
ataxia ≥24 h
Normal ND Developmental delay (motor and 
cognitive) (4 years)
19/M/35 months Yes (38.5) 2–23 h Partial and whole body 
(15–30 min) and ataxia 
≥24 h
Normal Normal Recovered (3.5 years)
      *    Depended on date child last seen and date of return of the questionnaire.   
  †  P r e c e d i n g   a d m i s s i o n .   
  ‡    Hemiplegia for <24 h.   
  §    Ictal, given thiopentone and transferred to paediatric intensive care unit at another hospital. Patient described as encephalopathic but duration not given – not possible to 
differentiate drug-induced from virus-induced encephalopathy.   
    CNS, central nervous system; HSV, herpes simplex virus; ND, not done; NK, not known.     
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ﬁ  t well with our ﬁ  nding of postnatal HSV CNS infection if 
allowance is made for exclusion of neonates. 
  HSE classically presents as an acute illness characterised 
by fever and encephalopathy together with behavioural dis-
turbances and/or motor deﬁ  cits and/or convulsions. No sign 
i s  p a t h o g n o m i c ,  b u t  i t  i s  n o t e w o r t h y  t h a t  i n  o u r  c h i l d r e n  
<3 years old, convulsions (generalised or focal) were present 
in every case. Similarly, two studies of postnatal HSE  2     7   report 
a predominance of convulsions in children aged <3 years 
as compared to older children who show a wider range of 
presentations. 
  Neuroradiology of postnatal HSE typically reveals focal 
haemorrhagic lesions localised to the medial temporal 
lobes, the insula and the orbital region of the frontal lobes 
of the brain. However, in our series the parietal lobes were 
frequently affected, conﬁ   rming previous ﬁ   ndings that in 
young children extra-temporal regions of the brain are often 
involved.  2     3     8   
  HSE outcome is difﬁ  cult to predict early on and particularly 
in very young children in whom subtle defects may appear 
later; it is therefore important that almost all of our cases 
were followed up at least a year after presentation. Long-term 
sequelae were reported in many of the children. Adverse out-
come was age-related and CT reﬂ  ected this as abnormalities 
were described in all the younger children but in none aged 
>11 months. Likewise, high numbers of red cells in the CSF, 
reﬂ  ecting haemorrhagic necrosis in the CNS, were conﬁ  ned to 
the younger age group. Of other recent studies of the long-term 
outcome of HSV CNS infection, that is, at least 6 months after 
onset,  2     9     10   one  10   reported that patients 3–35 months old were 
more likely to be severely disabled than older children. Our 
series further suggests that those <1 year old were at highest 
risk. Poor neurological outcome is associated with delayed ini-
tiation of aciclovir therapy and/or shorter courses of the drug 
but, although all children received aciclovir, the confound-
ing effects of inadequate treatment could not be addressed as 
this information was not collected by us nor in the study of 
Ito   et al  .  10   The inﬂ  uence of age of onset in relation to severity 
of long-term outcome requires prospective study taking into 
account the role of inadequate aciclovir therapy. 
  In conclusion, this survey documents the incidence of 
HSV-induced serious neurological disease in young children 
in Britain and emphasises that there are various presenta-
tions ranging from frank encephalitis to severe illness with 
fever and convulsions, and even a milder form lacking lengthy 
  encephalopathy. Disease was commoner in children aged 
2–11 months than in older children, and neurological seque-
lae and consequent severe disabilities showed the same trend. 
HSV CNS infection must always be considered in children 
presenting with convulsions even when apyrexial, without 
encephalopathy and with normal CT ﬁ  ndings. 
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